Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Provide Corporate Update

GlobeNewswire February 26, 2020

Collegium Announces Closing of the Nucynta Franchise Acquisition

GlobeNewswire February 13, 2020

Collegium Pharmaceutical, Inc. Prices $125.0 Million Convertible Senior Notes Offering

GlobeNewswire February 10, 2020

Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering

GlobeNewswire February 10, 2020

Collegium to Acquire U.S. Rights to Nucynta Franchise

GlobeNewswire February 6, 2020

Biohaven Appoints Michael Heffernan To Board Of Directors

PR Newswire January 31, 2020

Collegium Provides 2020 Financial Guidance

GlobeNewswire January 7, 2020

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire November 26, 2019

Collegium to Participate in Upcoming Investor Conference

GlobeNewswire November 8, 2019

Collegium Reports Third Quarter 2019 Financial Results

GlobeNewswire November 6, 2019

Collegium to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update

GlobeNewswire October 23, 2019

Collegium to Participate in Upcoming Investor Conference

GlobeNewswire September 25, 2019

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire September 3, 2019

Collegium Announces Scientific Presentations at PAINWeek 2019 National Conference

GlobeNewswire August 29, 2019

Collegium Reports Second Quarter 2019 Financial Results

GlobeNewswire August 7, 2019

Collegium to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update

GlobeNewswire July 24, 2019

Collegium to Present at Upcoming Investor Conferences

GlobeNewswire May 29, 2019

Collegium Reports First Quarter 2019 Financial Results

GlobeNewswire May 8, 2019

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire April 30, 2019

Collegium to Host Conference Call to Discuss First Quarter 2019 Financial Results and Provide Corporate Update

GlobeNewswire April 24, 2019